Methods of Encapsulation of Biomacromolecules and Living Cells. Prospects of Using Metal–Organic Frameworks

A. V. Sokolov, L. V. Limareva, P. V. Iliasov, O. V. Gribkova, and A. S. Sustretov

Abstract—The review discusses different methods of encapsulation and biomineralization of macromolecules and living cells. Main advantages and disadvantages of most commonly used carriers, matrices, and materials for immobilization of proteins, enzymes, nucleic acids, and living cells are briefly surveyed. Examples of delivery vehicles for multifunctional encapsulation of protein-like substances are presented. Particular attention is paid to prospects of using metal–organic frameworks in medicine and biotechnology.

Keywords: polymer nanoparticles, inorganic nanoparticles, metal–organic frameworks, immobilization, encapsulation, biomineralization

DOI: 10.1134/S1070428021040011

1. INTRODUCTION

Immobilization of biomacromolecules and cells underlies the key approach to the design of new biomaterials, catalysts, and medicines and development of bioprocesses. There are numerous immobilization methods, the most promising of which for biomedical purposes are encapsulation and biomineralization, since they provide protection from environmental factors, stabilization, and controlled release of the content.

Up to now, a large number of various carriers, matrices, and materials for encapsulation and biomineralization of biological components have been proposed. Among them, the most widespread are gel materials, micellar, vesicular, and membrane systems, organic and inorganic polymeric structures, as well as metal–organic frameworks (MOFs) (Fig. 1). Each type of carriers features structural and functional peculiarities, advantages, and disadvantages, and their choice in each particular case depends on the objectives of a study, immobilized component, and researcher’s preferences.

Nowadays, protein-based biologically active compounds and drugs, such as hormones, antioxidants, enzymes, enzyme inhibitors, vaccines, antitumor agents, etc., have gained wide application in medicine, food industry, and biotechnology. On the other hand, their use is associated with some limitations, the main of which are related to high sensitivity of proteins and medicines to denaturation, aggregation, or hydrolysis in the gastrointestinal tract (GIT), undesirable interactions of components of a medicine with each other or with other medicines, poor absorption of proteins in the GIT, hydrophobicity, instability and degradation on storage, toxicity, and immunogenicity of foreign protein components [1–5]. One of the approaches to overcome these limitations is based on encapsulation of proteins using appropriate carriers [1, 6–11]. For example, colloidal delivery systems suitable for encapsulation of proteins include microemulsions, emulsions, micelles, solid lipid nanoparticles, liposomes, polymersomes, sol–gels, and hydrogels [3, 12, 13].
Inorganic mesoporous particles (silicon dioxide nanoparticles, hydroxyapatite, calcium phosphates, etc.) and polymer-based particles, including those of protein nature, have been extensively used [14–19]. In particular, insulin was encapsulated in chitosan and pectin nano- and microparticles, which made it possible to avoid hormone injection and develop dosage forms for oral administration [20]. Liposomal forms of drugs and antigens are also widely used for these purposes, which makes it possible to overcome biocompatibility
problems and provides targeted delivery and protection from undesirable immune response. Liposomes are used in the design of vaccines to ensure induction of antibodies and T-cell reactions to associated antigen subunits [8].

On the other hand, the described technologies for encapsulation of biologically active protein-like substances are not free from some drawbacks which should be taken into account in their practical implementation. These include the need to standardize matrices with respect to size, shape, and particle charge, especially when controlled release of an encapsulated substance is necessary. In particular, owing to the small pore size of inorganic carriers, trapping of molecules of only a certain size is possible [21, 22]. In some cases, there is poor reproducibility of microspheres, as well as deactivation of a protein during preparation, storage, and release from the created particles. In order to avoid toxicity and undesirable interactions between the components of the resulting preparation, careful selection of ingredients of the encapsulating systems is required. The main factors limiting successful application of liposomes in practice are potential cytotoxic effects of liposomes, toxicity of charged liposomes [23, 24], their leakage, possible presence of trace amounts of organic solvents (ethanol, ether) in the final preparation [25], poor batch-to-batch reproducibility, low sorption of the drug payload [26], lack of effective sterilization methods [27–29], and stability [30–32] and scaling problems. Other disadvantages of using vesicular systems, including liposomes, as well as solid lipid particles, are their high cost, laborious production, susceptibility to degradation during storage, and the need to control aggregation of colloidal particles. Until now, problems associated with limited drug load volume of micellar systems and stability of formulations encapsulated therein have not been resolved [2, 5, 10, 26, 33].

In many cases, the above problems can be solved by using encapsulation matrices based on metal–organic frameworks (MOFs). They are characterized by structural rigidity which favors protein fixation and hence prevents protein denaturation or degradation. It was demonstrated [34] that insulin encapsulated in NU-1000 zirconium-based mesoporous MOF remains stable toward gastric juice and is not destroyed by pepsin, but it degrades in a phosphate buffer that mimics physiological conditions in tissues, which makes it possible to control its release. The composite material remains unchanged on heating above 50°C, so that the insulin structure is maintained intact. The obtained results can be used to develop alternatives to insulin pumps, as well as new formulations for the delivery of insulin.

Biomimetic methods have been developed for encapsulation of proteins in MOFs to deliver one or several proteins to cellular structures with the goal of finding new approaches to the treatment of tumors. The obtained hybrid materials conserved protein molecules on storage for several months. Chu et al. [35] described a biomimetic mineralization method for the synthesis of protein-encapsulating MOF nanoparticles (NPs) which preserved protein activity and protected proteins from enzyme-mediated degradation. Moreover, the developed platform was demonstrated to enable easy encapsulation of multiple proteins in single MOF NPs for their efficient co-delivery.

Encapsulation of hemoglobin in zeolite-like ZIF-8 MOF significantly enhanced its stability while maintaining the ability of encapsulated hemoglobin to transport oxygen in vivo with an efficiency of 80–90% relative to native hemoglobin. Experiments in mice showed that the resulting composite is not immunogenic; its surface charge is close to zero, which prevents protein adsorption on the surface. The composite nanoparticles are absorbed by macrophages approximately 3 times slower, and they do not change the activity of blood enzymes. The elimination half-life is 14 h, and the cytotoxicity of the composite is lower than that of bare ZIF-8 NPs. The composite decomposes at pH 5.0 in cell lysosomes, which reduces the risk of accumulation of nanoparticles in vivo. Administration of the composite significantly extended the survival time of mice subjected to hemorrhagic shock [36].

Biocatalysts, including enzymes, play an important role in medical and food industries and biotechnology [37, 38]. For biotechnological applications, of particular significance are increased stability and efficiency of enzymes and the possibility of their repeated use in biocatalysis, biotransformations, preparation of various products, etc. These goals can be achieved through the use of various carriers, such as dendrimers and dendrimeres, micelles, liposomes, polymer vesicles (polymersomes), emulsions, inorganic mesoporous nanoparticles of silicon dioxide, hydroxyapatite, etc. [21, 22, 39–41], as well as MOFs [42]. Encapsulation of enzymes as a version of their immobilization makes it possible to protect them from the action of aggressive media, maintain catalytic activity, deliver them to the body for therapeutic purposes, reduce the risk of allergic reactions, and combine biologically active sub-
stances into multienzyme complexes (nanoreactors) [40, 43–47].

In particular, a high antitumor effect of encapsulated L-asparaginase has been demonstrated. Encapsulation increased the proteolytic stability of the enzyme and weakened its recognition by antibodies, which reduced the potential frequency of drug administration and the risk of inducing immune response [40].

Caruso et al. [44] proposed a method for encapsulation of proteins via sequential multilayer coating of protein crystals with polymers using catalase as an example. Methodological simplicity of this approach and the stability of the resulting coating to the action of proteases were demonstrated.

Incorporation of acetylcholinesterase and some other enzymes into liposomes made it possible to stabilize them and protect from the action of proteases [45]. The preparation and use of liposomes for the encapsulation of various enzymes in the food industry were considered in [37]. Modern technologies provide a combination of several biologically active substances on a single carrier to produce multienzyme complexes. Van Hest et al. [47] described polymersomes with hierarchical immobilization of three enzymes (glucose oxidase, lipase, and horseradish peroxidase) as nanoreactors.

Limitations and problems related to encapsulation of enzymes are determined by the structure of the carriers; accordingly, these limitations can often be overcome by modification of the carrier structure. For example, the ability of polymersomes to retain and protect its load was enhanced through cross-linking of their membranes with special compounds and hydrophobic primary amines [41, 48]. Various lipids and proteins were introduced into the layers of liposomes to increase their stability [45]. In addition, a common problem in the encapsulation of enzymes in polymer capsules is unwanted desorption of biologically active substances during storage and delivery [49]. An alternative method for stabilizing enzymes while maintaining their catalytic properties is their encapsulation in MOFs (Fig. 2a).

It was shown [50] that MIL-100(Fe) MOF can be used to encapsulate pancreatic lipase as a reusable catalyst. The catalyst retained its activity over 8 cycles and was insensitive to acidity of the medium in the pH range 3.0–9.0; the catalytic activity did not change up to 70°C. The high capacity of semicrystalline MIL-100(Fe) with respect to lipase and lactase was demonstrated, and no more than 10% of enzyme molecules was lost during the technological process [51].

Zeolite-like imidazolate MOFs (ZIF) (unlike other MOFs, they can be synthesized under physiological conditions) were successfully used to encapsulate unstable enzymes such as peroxidase, urease, alcohol dehydrogenase, and glucose oxidase [52–54]. The resulting ZIF–enzyme showed a high resistance to denaturing solvents like DMSO, DMF, and alcohols [55]. An interesting example is encapsulation of enzymes in porous hydrogen-bonded organic frameworks (HOF) [56] which have no cytotoxic properties and possess large pore dimensions. However, while designing encapsulated enzymes of a similar structure, it is necessary to take into account that in some cases transition metal-based MOFs can exhibit a catalytic effect [57, 58].

3. ENCAPSULATION OF NUCLEIC ACIDS

Vector construction is a critical step in genetic engineering and therapy. Viral, plasmid, and other constructs based on nucleotide sequences are usually used as genetic vectors. Such vectors can be specific and/or nonspecific for certain target cells; they are capable of being inserted into the genome, providing constitutive or inducible expression of a transgene that replaces or compensates for defective or undesirable host genes, and carry or not carry replicative mechanisms, depending on their function. Recently, there has been growing interest in RNA interference technologies, as well as in genome editing methods based on CRISPR/Cas systems and their analogues, which open broad prospects for gene therapy. A common drawback of such structures is their immunogenicity, as well as a number of limitations in the targeted delivery and transformation of target cells in vivo, which are associated, in particular, with the need to protect vectors from the immune system and nucleases. One way to overcome these limitations is encapsulation of transgenes into various carriers with or without vectors; in the latter case, vector functions, i.e., transgene delivery into the cell and ensuring its functioning therein, are performed by the carrier (Fig. 2b).

Polymer matrices and micellar structures are generally not used for encapsulation of nucleic acids due to difficulties in the transformation of such vectors. Recent publications reported the use of MOFs as abiotic analogs of genetic vectors due to the possibility of their endocytosis. The presence of an extended hydrogen bond system in the structure of nucleic acids and comparable pore diameters in MOFs provides the possibility for the encapsulation process to involve.
both biomineralization and reversible adsorption of nucleic acids within MOF pores [53, 59]. In the latter case, the release and uptake of nucleic acids can be controlled by changing properties of the carrier without destroying it, which makes it possible to implement a controlled platform for genetic manipulation. This approach was demonstrated [60] using nickel-based isoreticular MOF (Ni-IRMOF-74), where precisely tuned pore diameter was selected for reversible interaction with single-stranded DNA, and successful transfection of primary mouse immune cells (CD4+ T-cells) and human immune cells (THP-1) was performed with an efficiency of 92 and 30%, respectively. Another MOF, namely ZIF-8, was used as a transfection vehicle for progenitor cells from the Langerhans islets [61]. The low toxicity and ease of use of such a carrier was demonstrated. Nanocomposites based on zirconium MOF NU-1000 and small interfering RNA [62] were used for gene knockdown in the HEK293 cell line.

In addition to interfering nucleic acids and other oligonucleotides, plasmid DNA encoding the production of the fluorescent protein pGFP was encapsulated in ZIF-8 [63], and successful transfection of the PC-3 cell culture with the resulting material was performed. It was noted that due to the slow release and expression of foreign DNA, as well as stabilizing properties of the MOF, the cytotoxicity of this transfection method was significantly lower than that of analogs.

4. ENCAPSULATION OF CELLS AND MICROORGANISMS

Encapsulation and biomineralization of cells are widely used in various fields of biotechnology and provide a number of advantages, including, apart from reduced consumption of the biomaterial, its protection from aggressive environment, controlled release, and repeated use of immobilized agents, the formation of spatial structures that mimic body tissues, biofilms, etc. The use of some gels and polymers makes it possible to optimize the state of cells and thereby contribute to their stability or modulate their activity [64]. All this ensures the efficiency of using immobilized biocomponents in cell cultivation [65], biofuel production [66], biotransformation of various compounds, and other biotechnological processes associated with biocatalysis, in particular during environmental remediation [67] and therapeutic use (e.g., for wound healing [68, 69]), as well as for bioanalytical purposes (e.g., as components of biosensor receptors).

A promising approach is based on the possibility of obtaining structures similar to biological membranes, organs, and tissues [70] with the goal of using them as implants or in tissue engineering [71–73]. The method and the carrier are selected on the basis of the stability of biomaterial and its activity, including diffusion properties of the carrier. In most cases, cells are immobilized by adsorption or inclusion in gel and polymer matrices. Covalent binding by difunctional agents is used relatively rarely due to toxicity of this method for cells [74, 75]. Various membranes [76–82], filter paper [83, 84], carbon materials [85], etc., are used as carriers for adsorption. One of the main advantages of the adsorption method is its technological simplicity. Furthermore, adsorption is a “soft” immobilization method, which usually exerts minimum damage to cells [86]. The stability of indications for the use of sorbed cells and enzymes is usually quite high. Functioning of enzymes and cells without loss of
activity for several weeks or even months was noted in a number of publications [80, 87, 88]. All these factors make adsorption one of the most preferred techniques. Immobilization of cells within MOFs can also be achieved through adsorption, covalent binding on the MOF surface, incorporation into pores of the carrier, coprecipitation, and in situ synthesis [89].

Gel encapsulation is used in biotechnology approximately as often as adsorption, and it is practically indispensable when microorganisms are poorly retained on the carrier. In the general case, encapsulation of cells in gel or polymer matrices is more advantageous than adsorption due to higher stability of the cells [90]. In addition, some polysaccharide gels (e.g., agar gels) reduce the toxic effect of aromatic compounds on cells [91], which is an important criterion for their use. Agar [92], calcium alginate [74, 93–95], carrageenan [96], gelatin, and collagen gels [97–99] and polyvinyl alcohol (PVA) [100–102] are widely used. Although polymerization of these carriers is performed under harsh conditions (high temperature or ionic strength of the medium or UV irradiation), they provide high stability of the biomaterial and reproducibility of its operation. Polyacrylamide gel is used quite often [103] despite its toxicity. Other carriers such as PVA-based cryogels [104, 105], ENT/ENTP photocrosslinked polymers (polymer mixture based on polyethylene or polypropylene glycol, hydroxyethyl acrylate, and isophorone diisocyanate, which is polymerized under near UV irradiation) or modified PVA [106], granules and films based on polyvinyl chloride [107], hydrogels based on chitosan [108–110], polycarboxamoyl sulfonate [111, 112], and polyurethane [113, 114], peptide polymers [115], biotin-avidin linkers [116–118], sol-gel matrices based on aluminum oxide [119] or composite polymers [120–123], as well as electropolymerizable polyaniline films [124–127] and other compounds [128, 129], and nanostructured materials (including carbon nanotubes and metal nanoparticles) [130–137] should also be noted. A common disadvantage of encapsulation in gels and polymers is diffusion restrictions imposed by the carrier nature, which in some cases appreciably reduce the rate of biocatalysis and the activity of biocomponents.

The use of MOFs as encapsulating matrices leads to the formation of crystalline extracellular structures similar to those arising from mineralization with inorganic salts. However, in this case, the extracellular structure has an ordered pore structure and selective permeability to ions and low-molecular-weight compounds, which has a specific effect on the cell life cycle and functioning (Fig. 2c).

Liang et al. [138] showed that ZIF-8 (zeolitic imidazolate framework) can be crystallized on the surface of Saccharomyces cerevisiae and Micrococcus luteus to form a protective coating on the respective cell walls, which provided almost 90% survival in the presence of lyticase, as well as under the action of antibiotics. This demonstrated homogeneity of the coating with respect to both biomacromolecules and relatively low-molecular-weight compounds. In addition, the bio-mineralization was found to induce cell hibernation which can be controlled by introducing a compound that lyases the exoskeleton (e.g., EDTA). When β-galactosidase, an enzyme which is untypical of S. cerevisiae and capable of decomposing lactose into natural nutrients, was immobilized on the surface of the exoskeleton, the nutrients were assimilated through the pores of ZIF-8, leading to enhanced survival and adaptation to oligotrophic conditions [139].

Bio-mineralization of the anaerobic bacterium Moorella thermoacetica with a monomolecular layer of MOF based on zirconium and 1,3,5-tris(4-carboxyphenyl)benzene significantly increased its survival under aerobic conditions. In this case, cytoprotection was achieved due not only to isolation of cells from the environment but also to the catalytic action of MOF which traps reactive oxygen species at unsaturated coordination sites of zirconium oxo clusters. An interesting fact was the ability of bacteria wrapped by MOF monolayer to reproduction, which was provided by the elasticity of the cytoprotective layer that does not prevent cell division [140].

Bio-mineralization of cellular structures can have functions opposite to protective ones. Thus, effective photodynamic ablation of bacterial biofilms was performed using composite materials based on porphyrin-containing MOFs capable of generating singlet oxygen [141], which can find application in both medicine and biotechnology.

Apart from cellular structures, fragments of cells and viral particles used as vaccines can be subjected to bio-mineralization to increase their stability and regulate immunological reactivity through gradual release of antigens [142–144]. Bacterial cell membranes can be utilized as a scaffold for MOF to form microcapsules with selective release of their content [145]. In some cases, MOFs can have a separate protective function, e.g., that similar to antifreeze proteins which prevent ice crystal growth; this can be used for cryopreservation of erythrocytes [36].
### Table 1. Characteristics of different matrices for encapsulation of biomaterials

| Encapsulating carrier | Load capacity | Particle size | Pore/network cell size | Multiple encapsulation | Storage stability | Stability under physiological conditions | Toxicity$^a$ | Biodegradability | Fabrication complexity |
|-----------------------|---------------|---------------|------------------------|------------------------|------------------|------------------------------------------|-------------|-----------------|---------------------|
| MOF                   | 1–130% [164]  | $10^{-8}–10^{-3}$ m | 5–100 Å | Yes | High | Controllable (depending on the ligand and metal nature) | Depends on the metal center and crystal size | Depends on the ligand and metal nature | Low |
| Liposomes             | 42–96% [25, 165, 166] | 20 nm–300 μm [167–170] | – | Yes [171] | Moderate (one to several months) [165, 167] | Low [169] 0.6 to 13.8 h [172] | Nontoxic [171] | High [171, 173] | High [26, 31] |
| Micelles              | 4–20% [174, 175] | 10–100 nm [176] | – | Rarely [10, 177] | Low | Depends on the polymer nature [174] | Low [14] | Variable [174] | Low [177] |
| Organic gel–polymer matrices | 90–800% [178, 179] | 20–200 nm [180] to hundreds of microns | 0.1–100 nm | Yes | Moderate | Low | Variable [5, 181] | High [5] | Relatively low |
| Inorganic matrices    | 22–41% [18] 1.7% [19] Up to 20% [182] 23–100% [21] | 30–280 to 2000 nm [21, 22, 183, 184] | 2–3 nm to 2–3 μm [21, 180, 183] | Yes [180] | High | Insufficient data (up to 15 days) [21] | Variable [19, 21, 22, 180, 183–186] | Under extensive study [21, 183, 186] | Low |
| Polymersomes          | 10–60% [187] | 5 nm–5 μm [176] | – | Yes [188] | Up to 6 months or more [167] | Depends on the structure of amphiphilic block copolymer [167] | Depends on the structure of amphiphilic block copolymer [188] | Variable | High [189] |

$^a$ The matrix a priori consists of nontoxic components.
5. MULTIFUNCTIONAL ENCAPSULATION

The development of highly effective drugs for poly-modal therapy of oncological and infectious diseases requires simultaneous delivery or sequential release of biomolecules. These problems can be solved through automated formation of complex structures with high spatial resolution, containing immobilized cells and enzymes. Inkjet printing was used [146] to create high-density matrices with encapsulated bacterial cells. An inkjet printer was also employed to immobilize cells conjugated to single-stranded DNA on a surface modified with complementary DNA [147]. A similar approach was utilized previously for enzymes, DNA, and antibodies [148–151]; however, its application to intact cells is a rare case. Furthermore, the use of scanning probe lithography to obtain carriers based on microcellular structures containing microbial cells has been described [152]. Such matrices are in demand in the fields of cell biology, immunology, and drug development. As well as organic structures, MOFs can be used to encapsulate dissimilar molecules. For example, simultaneous immobilization of nickel–palladium nanoparticles and glucose oxidase in ZIF-8 led to the formation of self-organized crystal structures with enzymatic properties, and glucose sensors were developed on the basis of such structures [153]. When nickel–palladium nanoparticles were replaced by Fe₃O₄ nanoparticles, the composite became magnetically susceptible [154], which can be used to create controlled biocatalysts.

Metal–organic frameworks for simultaneous encapsulation of several enzymes for biomedical purposes have been designed and synthesized [155]. Zirconium-containing MOF UiO-66 was shown [156] to simultaneously absorb glucose oxidase and peroxidase. The resulting biocatalyst displayed a higher activity than that of the free enzymes; however, the carrier lost enzymes within a few days due to the equilibrium nature of adsorption. Enzymes encapsulated in MOF were used to catalyze multienzyme cascade reactions; in particular, carbon dioxide was converted to formate using a layered structure consisting of MIL-101(Cr) and HKUST-1 with immobilized carbonic anhydrase and formate and glutamate dehydrogenases [157]. This study provided an important evidence of the possibility of developing biomimetic methods for removal of greenhouse gases.

The presence of catalytically active metal centers in the MOF structure, originating from local defects and disturbances in the crystal lattice, in combination with the molecular recognition effect determined by the strictly ordered shape and interior of the pores, as well as with a high surface area, in some cases endows the carrier with a catalytic activity similar to the activity of native enzymes [158]. At present, structures with catalase [159], peroxidase [160, 161], and laccase [162] activities have been characterized. In future, such MOFs can be used as analogs of enzyme markers for the development of enzyme immunoassay and immunochromatographic assay systems.

The possibility of encapsulation of DNA enzymes together with low-molecular-weight compounds was demonstrated by the synthesis of ZIF-8 nanoparticles containing DNA molecules and a photosensitizer [163]. It was found that the resulting nanomaterial effectively penetrates without degradation tumor cell membranes in BALB/c female nude mice bearing MCF-7 tumors and allows simultaneous photodynamic and gene therapy of cancer.

Brief characteristics, advantages, and disadvantages of various carriers for encapsulation of biocomponents are collected in Table 1.

The above considered aspects make encapsulation and biomineralization promising for the development of biomaterials with controlled parameters. Such materials can find diverse applications in various fields of biotechnology and medicine.

6. CONCLUSIONS

Encapsulation is one of the most common methods for stabilizing biomacromolecules and living cells. Due to the wide field of application and numerous medical and biotechnological problems, almost the entire range of biocompatible or nontoxic materials capable of forming structured objects have been used for encapsulation. The general requirement for encapsulating agents is the stability of the content to effects of the external environment, invariability of their structure and composition over time, high load capacity, and biodegradability. However, in most cases it is difficult to meet all these requirements simultaneously, since organic colloidal structures are thermodynamically unstable, while inorganic matrices are difficult to decompose under physiological conditions or their capacity is low. In this respect, MOFs are most appropriate as encapsulating agents. These carriers are characterized by high capacity, resistance to drying and denaturing agents, as well as by the possibility of being imparted with controlled properties, flexibility of design, and a wide variety of potentially realizable
topologies. The presence of an ordered pore system of pores that are permeable to certain molecules, thermal stability, and the possibility of selective degradation of MOFs due to the difference in physiological conditions in the intra- and extracellular space make it possible to implement new biotechnological processes and create medical composite materials with desired properties. Thus, the use of MOFs for encapsulation and mineralization of biomacromolecules and living cells is a dynamically developing area with undoubted prospects for practical application, including drug delivery, design of biocatalysts for biotechnological purposes, and preparation of cellular structures for tissue regeneration. Nowadays, the use of MOFs is limited by a poor diversity of biocompatible organic ligands and toxicity of metals and by the lack of information on the potential use of previously unused metals and ligands. However, a significant increase in the number of studies of the properties of MOFs and a short period of time elapsed from their discovery give reason to believe that new therapeutic agents and methods, dosage forms, and highly effective biocatalysts will be developed in the nearest future.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

1. Ye, C. and Chi, H., Mater. Sci. Eng., C, 2018, vol. 83, p. 233. https://doi.org/10.1016/j.msec.2017.10.003
2. Perry, S.L. and McClements, D.J., Molecules, 2020, vol. 25, p. 1161. https://doi.org/10.3390/molecules25051161
3. Pérez-Luna, V.H. and González-Reynoso, O., Gels, 2018, vol. 4, p. 61. https://doi.org/10.3390/gels4030061
4. Henriksen, P.A., Heart, 2018, vol. 104, p. 971. https://doi.org/10.1136/heartjnl-2017-312103
5. Sikder, S., Gote, V., Alshamrani, M., Sicotte, J., and Pal, D., Expert Opin. Drug Delivery, 2019, vol. 16, p. 1113. https://doi.org/10.1080/17425247.2019.1662785
6. McClements, D.J., Adv. Colloid Interface Sci., 2018, vol. 253, p. 1. https://doi.org/10.1016/j.cis.2018.02.002
7. Richard-Carpentier, G. and DiNardo, C.D., Hematology, 2019, vol. 2019, p. 548. https://doi.org/10.1182/hematology.201900059
8. Watson, D.S., Endsley, A.N., and Huang, L., Vaccine, 2012, vol. 30, p. 2256. https://doi.org/10.1016/j.vaccine.2012.01.070
9. Schwendener, R.A., Ther. Adv. Vaccines Immunother., 2014, vol. 2, p. 159. https://doi.org/10.1177/205103614541440
10. Zhang, Y., Huang, Y., and Li, S., AAPS PharmSciTech, 2014, vol. 15, p. 862. https://doi.org/10.1208/s12249-014-0113-z
11. Gupta, S., Kaushal, A., Kumar, A., and Kumar, D., Int. J. Biol. Macromol., 2017, vol. 105, p. 905. https://doi.org/10.1016/j.ijbiomac.2017.07.126
12. Wang, X., Ahmed, N.B., Alvarez, G.S., Tuttolombo, M.V., Helary, C., Desimone, M.F., and Coradin, T., Curr. Top. Med. Chem., 2015, vol. 15, p. 223. https://doi.org/10.2174/1568026614666141229112734
13. Venditti, I., J. King Saud Univ. Sci., 2019, vol. 31, p. 398. https://doi.org/10.1016/j.jksus.2017.10.004
14. Akash, M.S.H., Rehman, K., and Chen, S., Pharm. Dev. Technol., 2016, vol. 21, p. 367. https://doi.org/10.3109/10837450.2014.999785
15. Liu, H., Cui, Y., Li, P., Zhou, Y., Chen, Y., Tang, Y., and Lu, T., Anal. Chim. Acta, 2013, vol. 776, p. 24. https://doi.org/10.1016/j.aca.2013.03.040
16. Tarihi, M., Greige-Gerges, H., and Elaissari, A., Int. J. Pharm., 2017, vol. 522, p. 172. https://doi.org/10.1016/j.ijpharm.2017.01.067
17. Truffi, M., Fiandra, L., Sorrentino, L., Monieri, M., Corsi, F., and Mazzucchelli, S., Pharmacol. Res., 2016, vol. 107, p. 57. https://doi.org/10.1016/j.phrs.2016.03.002
18. Andersson, J., Rosenholm, J., Areva, S., and Lindén, M., Chem. Mater., 2004, vol. 16, p. 4160. https://doi.org/10.1021/cm0401490
19. Meng, H., Xue, M., Xia, T., Zhao, Y.-L., Tamanoi, F., Stoddard, J.F., Zink, J.I., and Nel, A.E., J. Am. Chem. Soc., 2010, vol. 132, p. 12690. https://doi.org/10.1021/ja104501a
20. Maciel, V.B.V., Yoshida, C.M.P., Pereira, S.M.S.S., Goycoolea, F.M., and Franco, T.T., Biomacromolecules, vol. 2)
21. Smistad, G., Jacobsen, J., and Sande, S.A., Gels, 2018, vol. 105, p. 905. https://doi.org/10.1016/j.gels.2017.09.017
22. Engineering of Nanobiomaterials (Applications of Nanobiomaterials, vol. 2), Grumezescu, A.M., Amsterdam: Elsevier, 2016, vol. 2, p. 564.
183. *Fundamental Biomaterials. Ceramics*, Thomas, S., Balakrishnan, P., and Sreekala, M.S., Eds., Duxford: Woodhead Publishing, 2018.

184. Lu, F., Wu, S.H., Hung, Y., and Mou, C.Y., *Small*, 2009, vol. 5, p. 1408. https://doi.org/10.1002/smll.200900005

185. Chung, T.-H., Wu, S.-H., Yao, M., Lu, C.-W., Lin, Y.-S., Hung, Y., Mou, C.-Y., Chen, Y.-C., and Huang, D.-M., *Biomaterials*, 2007, vol. 28, p. 2959. https://doi.org/10.1016/j.biomaterials.2007.03.006

186. Slowing, I.I., Vivero-Escoto, J.L., Wu, C.W., and Lin, V.S., *Adv. Drug Delivery Rev.*, 2008, vol. 60, p. 1278. https://doi.org/10.1016/j.addr.2008.03.012

187. Lin, F.-Y., Cheng, C.-Y., Huang, Y.-H., and Tung, S.-H., *Polymer*, 2018, vol. 134, p. 117. https://doi.org/10.1016/j.polymer.2017.11.060

188. Das, S., Sharma, D.K., Chakrabarty, S., Chowdhury, A., and Sen Gupta, S., *Langmuir*, 2015, vol. 31, p. 3402. https://doi.org/10.1021/la503993c

189. Dionzou, M., Morere, A., Roux, C., Lonetti, B., Marty, J.D., Mingotaud, C., Joseph, P., Goudonneche, D., Payre, B., Leonetti, M., and Mingotaud, A.F., *Soft Matter*, 2016, vol. 12, p. 2166. https://doi.org/10.1039/c5sm01863c